DISHMAN

The Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Today i.e. 16th April 2007, the Board of Directors of the Company has allotted 7,59,767 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 3,000,000, into equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 7,22,13,077 equity shares of Rs.2/- each to 7,29,72,843 equity sha

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "The Company has designated following e-mail ID of the grievance redressal division / compliance officer exclusively for the purpose of registering complaints by investors.: grievance@dishmangroup.com."

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "the Board of Directors of the Company has decided to withdraw the decision for the issue of Foreign Currency Convertible Bonds FCCBs) and/or other instruments which was earlier decided in its meeting held on 29th January, 2007. Consequently, it is also decided to cancel and not to hold the Extra Ordinary General Meeting (EGM) of the Members of the Company which was earlier decided to be convened on Thursday, the 5th day of April, 2007 to transact, inter alia, the special business relating to the issue of Foreign Cur

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange a copy of the Notice of Extra Ordinary General Meeting of the Members of the Company to be held on April 05, 2007 to transact, interalia, the special business relating to the issue of Foreign Currency Convertible Bonds (FCCBs)/ECBs convertible into shares/Qualified Institutional Placement to QIBs up to USD 50,000,000. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/co

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Dishman announces a marketing Joint Venture (JV) in Japan with Azzurro Corporation. Dishman will hold 85% stake and Azzurro will have 15 % in this JV. Azzurro is a 30-year-old marketing firm and well-known in Japanese market. New company will be called DISHMAN JAPAN LTD. (DJL) and its office will be located in Tokyo. DJL will market the products and services of DISHMAN, CARBOGEN-AMCIS AG, Switzerland and of SYNPROTEC DCR LTD., UK, in Japan and South Korea. Mr. Takeshi Yokouchi will head DJL as Managing Director. He h

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that " it is decided to convene an Extra Ordinary General Meeting of the Members of the Company to be held on Thursday, the 5th day of April, 2007 at Ahmedabad to transact, inter-alia, the special business relating to the issue of Foreign Currency Convertible Bonds (FCCBs)/ECBs convertible into shares /Qualified Institutional Placement to QIBs up to USD 50,000,000".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Mr. Divyabhash C. Anjaria ceased to be a Director of Dishman Pharmaceuticals and Chemicals Ltd. ("Company") upon resignation with effect from 9th February, 2007 and his resignation has been accepted by the Board of the Company. Consequent to this, Mr. Divyabhash C. Anjaria also ceased to be a member of Audit Committee and Remuneration Committee of the Company."

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Today, i.e. on 29th January, 2007, the Board of Directors of the Company has allotted 30,39,068 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 12,000,000, into equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 6,91,74,009 equity shares of Rs. 2/- each to 7,22,13,076 equi

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board Meeting held on January 29, 2007, the Board has decided to issue unsecured Foreign Currency Convertible Bonds (FCCBs) up to USD 50 Million with an authority to the Managing Director to initiate further actions in the matter.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today, i.e. on 12th January, 2007, the Board of Directors of the Company has allotted 1,26,627 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 5,00,000, into equity shares of the Company, by the FCCB holder. Consequently, the paid-up equity share capital of the Company has increased from 6,90,47,382 equity shares of Rs. 2/- each to 6,91,74,008 equity shares of

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that " Dishman is pleased to announce second joint venture in Saudi Arabia with Takamul Investments Holding Company (Takamul), a group company of capital Advisory Group, to manufacture Hospital Disinfectant formulations, Anti-cancer Drug formulations ad Dry Powder inhaler (DPI). Takamul will discuss with Saudi Arabian formulation companies to join this JV arrangement, so that the JV can utilize the marketing and supply chain of such pharma companies. As per the report given by the capital Advisory Group, Saudi Arabian inha

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "on 18th December, 2006, the Board of Directors of the Company has allotted 1,26,627 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 5,00,000, into equity shares of the Company, by the FCCB holder. Consequently, the paid-up equity share capital of the Company has increased from 6,89,20,754 equity shares of Rs. 2/- each to 6,90,47,381 equity shares of Rs.2/- each.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that on November 17, 2006, the Board of Directors of the Company has allotted 1,26,627 equity shares of Rs. 2/- each of the Company at a premium of Rs. 170/- per equity share upon exercise of option of conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US $ 5,00,000 into equity shares of the Company, by the FCCB holder. Consequently, the paid-up equity share capital of the Company has increased from,6,87,94,127 equity shares of Rs. 2/- each to 6,89,20,754 equity shares of Rs. 2/- each.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Carbogen-Amcis AG, the Swiss company recently acquired by Dishman, announces a capital investment of US $ 8 million for their additional Oncology production line. The investment is being made because Carbogen-Amcis' capacity is fully augmented as of now and two of its customer's Oncology products have successfully cleared phase-III and the customers will be filing market authorization in near future. The investment to be made will be out of Carbogen-Amcis' cash accruals.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman Infrastucture Ltd., a company promoted by Dishman Pharmaceuticals and Chemicals (DPCL), has obtained "in principle" approvals from the Board of Approvals, Ministry of Commerce and Industry, Government of India for setting up of one Engineering SEZ and one Pharmaceuticals and Fine Chemicals SEZ in Gujarat. The total investment will be around Rs. 650 crores for both the SEZs, to be made over next three to five years and will be funded through a combination of Debt / Equity and internal accruals in the said compa

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the Board of Directors of the company held on October 18,2006, the Board of the company strongly acknowledges the performance of CARBOGEN AMCIS AG, (a research and hi-potent product manufacturing Company as acquired by the company in August, 2006 and whose results are consolidated with the results of the company during the quarter ended September 30,2006) and members of the Board of the company also commended the team of CARBOGEN AMCIS AG for their extra ordinary performance, by passing a specific re

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that there was a fire due to short circuit in one of the Raw Material Warehouses in the Bavla factory premises of Dishman Pharmaceuticals and Chemicals Limited, at around midnight on August 25, 2006. The fire was brought under control in due course and there was no injury caused to any person. As per preliminary estimates, the value of stock/assets destroyed due to fire would be around Rs.10 to Rs.12 crores. However, the company has full insurance cover available. Further, the warehouse is located at an isolat

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the company ("Dishman") on August 23,2006 announced that it has acquired CARBOGEN AMCIS AG ("CA"), a Swiss Research based company with the three production facilities in Switzerland for manufacture of high potent high value products from Solutia Europe SA/NV ("SESA"). Dishman paid to SESA over US$ 75 million (inclusive of around Us $ 9 million for working capital) and took over the shares and assets of CARBOGEN AMCIS, through its wholly owned subsidiary namely Dishman Pharma Solutions AG ("DPS") in Burssels on August

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company has decided to promote the Projects of Special Economic Zone, one for Pharmaceuticals & Fine Chemicals Segment and another for Engineering Segment through its subsidiary company.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has joined as a Joint Venture partner in Saudi Arabian Joint Venture formed by the Company alongwith Arab Company for Drug Industries and Medical Appliances (ACDIMA) and Takamul Holding Company (THC) for new API project. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Annual General Meeting of the Members/Shareholders of the Company held on June 29, 2006, members have approved and passed, among others, the following resolutions:- (i) In respect of the Financial year 2005-2006 a final dividend @ 35% (Rs.0.70 Per share) on the paid up equity shares of the Company has been declared by the members. (ii) Members of the Company have also decided, approved and resolved to appoint M/s. Deloitte Haskins & Sells, Chartered Accountants, Ahmedabad as Statutory Auditors of the Company to

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company (Dishman) has developed a unique position in bulk actives in the area of disinfectants. Company produces as many as 15 disinfectant bulk actives. Apart from popular hospital disinfectants such as Cetrimide and Chlorhexidine, the company's R&D has developed very sophisticated molecules such as Octenidin and Mecetronium Etho Sulphate. These disinfectants are not being offered by any company in the world with appropriate master Drug Master File (DMF). Dishman has filed DMF in Europe for both these actives. Ba

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding an announcement dated May 24,2006 titled "Dishman Reaches Agreement To Acquire Solutia's Pharmaceutical Services Business". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on May 23, 2006 has recommended the final dividend @ 35% for the financial year 2005-06 on the paid up equity share capital of the Company.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company has decided and resolved to convene and hold Annual General Meeting of the Members of the Company on June 29, 2006 and the Register of Members & Share Transfer Books of the Company will remain closed from June 23, 2006 to June 29, 2006 (both days inclusive) for determining the entitlement of Final Dividend as recommended as well as for holding the Annual General Meeting on June 29, 2006.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board of Directors of the Company at their meeting held on May 23, 2006, the following decisions were taken by the BoDs of the Company : (a) Resolution in respect of the Re-appointment of Mrs. Deohooti J. Vyas as Wholetime Director of the Company for a further period of 5 (five) years w.e.f. September 03, 2006 and increase in remuneration payable to her has been passed, subject to approval of the Members in ensuing Annual General Meeting to be held on June 29, 2006. The present term of appointment of Mrs. Deoh

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman Ties Up a Syndicated Loan Upto US$ 60.00 Million With ICICI Bank For Funding The Potential Acquisition in Europe.

News Verification : The media had reports on May 15, 2006 that Dishman Pharmaceuticals and Chemicals Limited is closer to formalising an acquisition in Switzerland. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Dishman Pharmaceuticals and Chemicals Limited has vide its letter inter-alia stated, "As a matter of strategy, the Company has been looking at acquisitions outside India, in accordance with the authority a

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the company has successfully complete US FDA inspection for its facility located at Bavla, which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay Pharmaceuticals, BV, a fortune 500 company. Dishman is one of the two companies in the world with whom Solvay has entered into a long-term agreement for supply of newly developed molecule, whose patent is to expire in 2013. With this event, Solvay will source its requirements for US markets from Dishman. Solvay has incre

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the change in shareholding in respect of persons holding more than 5% shares of Dishman Pharmaceuticals Limited as follows : 1)HDFC Trustee Company Limited A/c HDFC Equity Fund holds 17,04,975 shares(2.48%) and HDFC Trustee Company Limited A/c HDFC Prudence Fund holds NIL shares. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

HDFC Asset Management Company Limited has informed the Exchange that with respect to the aggregate holding of the Schemes of HDFC Mutual Fund in Dishman Pharmaceuticals Limited("the Company"), there has been a decrease in the shareholding of the Company by the Schemes of HDFC Mutual Fund by 2.58% as of March 28,2006. As on March 28, 2006, the aggregate holding of the Schemes of HDFC Mutual Fund in the company is 2.48% of the paid up equity share capital of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcemen

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Bhadra-Raj Holdings Pvt. Ltd(promoter group company) has sold 10,09,850 shares of Dishman Pharmaceuticals And Chemicals Limited on February 01, 2006. The mode of sale is Market Sale and the shareholding of Bhadra-Raj Holdings Pvt. Ltd after the said sale is 6,00,000 shares aggregating to 0.87% of the share capital of Dishman Pharmaceuticals And Chemicals Limited.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Mr. Rajnikant T. Vyas, Director of the Company has sold 15,00,000 shares of Dishman Pharmaceuticals And Chemicals Limited on January 31, 2006. The mode of sale is Market Sale and the shareholding of Mr. Rajnikant T. Vyas after the said sale is 12323300 shares aggregating to 17.95% of the share capital of Dishman Pharmaceuticals And Chemicals Limited.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the company announces as under:- 1) Company has acquired 80,000 sq.mt industrial plot in Shanghai Chemical Industry park (SCIP). This land will cost approximate 4 million dollars, out of which 50 % is payable after obtaining business licence and balance 50%, within two years of agreement. Company intends to start production of quats and intermediates in the first phase and contract manufacturing facilities including US-FDA compliant API plants in the second phase within two years. Total first phase investments will b

Clarification of News : The media had reports on January 05, 2006 that Dishman Pharmaceuticals and Chemicals Limited is planning to set up a greenfield project at China's Shanghai Chemical Park. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Dishman Pharmaceuticals and Chemicals Limited has vide its letter inter-alia stated, "We would like to clarify that the planning of project in China is in preliminary stage an

Clarification of News : The media had reports that Dishman Pharmaceuticals and Chemicals Limited is planning to set up a greenfield project at China's Shanghai Chemical Park. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Dishman Pharmaceuticals and Chemicals Limited.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the company has acquired a Bern,Switzerland based contract research company,M/s IO3S Ltd.(IO3S),through its 100% wholly owned Switzerland based subsidiary company M/s.Dishman Switzerland Limited.Further, details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the AGM of the Members / Shareholders of the Company held on September 26, 2005,members have approved and passed the resolution for the reappointment of Shri Rajnikant T. Vyas as a Chairman & Managing Director of the Company for a further period of 5 (Five) years w.e.f. July 01, 2005. The Company has further informed the Exchange that, Members of the Company have also decided, approved and resolved to the sub-division of each of the existing issued, subscribed and paid-up 1,37,33,500 Equity Shares of the face valu

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has fixed October 28, 2005 as Record Date for the purpose of determining the shareholders eligible to receive the split / sub-divided shares of Rs.2/- each.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the BODs of the company held on August 31, 2005, it was decided and resolved, inter-alia, to the sub-division of each of the existing issued, subscribed and paid-up 1,37,33,500 Equity Shares of the face value of Rs. 10/- (Rupees Ten only) each in the capital of the Company into five Equity Shares of the face value of Rs. 2/- (Rupees two only) each credited as fully paid up. The company has further informed that each of the 62,66,500 un-issued equity shares of the face value of Rs.10/-(Rupees Ten onl

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that on August 22, 2005 the Company has received a Listing Approval from the Stock Exchange of Singapore ("SGX-ST") for its US$ 50,000,000 0.5% Unsecured Foreign Currency Convertible Bonds due 2010 and the said Bonds have been listed and quoted on the said SGX-ST w.e.f. August 22, 2005.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Directors of the Company have, by passing a circular resolution on August 18, 2005, with the consent of all the Directors, consented to receive the payment for and to allocate US$ 50 million of Unsecured Foreign Currency Convertible Bonds ("FCCBs" or "Bonds") to the subscribers on the Basis of Allotment proposed by the Rabobank International, Singapore Branch, Lead Manager to the FCCBs Issue.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Meeting of the Board of Directors of the Company held on July 29, 2005, the Board has discussed inter alia, the followings: 1) Approves the proposal for Acquisition of a contract research company in Switzerland Mr. J.R. Vyas, Managing Director of the Company has been authorised to negotiate and conclude the transaction. 2) Approves the proposal for Joint Venture in Saudi Arabia for production of Glucosamine salts and Mr. J.R. Vyas, Managing Director of the Company has been authorised to negotiate and conclude t

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the baord meeting held on July 29,2005 it was decided and resolved to convene and hold the aGM of the members of the company on September 26,2005. The Register of Members and Share Tranfer Books of the Company will remain closed from September 20, 2005 to September 26, 2005 (both days inclusive) for determining the entitlement of final dividend, which was recommended by the Board @ 25% for the year 2004-05 and also for holding the AGM on September 26, 2005.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange of the following: (1) DISHMAN SIGNS DEVELOPMENT AND SUPPLY AGREEMENT WITH NU SCAAN, U. K. : Dishman Pharmaceuticals and Chemicals Limited announces that it has entered into an agreement with a leading British company NU SCAAN, for the development & manufacture of Bulk Actives for Neutraceutical products. NU SCAAN is marketing these products in Europe including UK, North America, Australia, New Zealand, South Africa, Japan etc. This agreement recognizes the R&D capabilities of the Dishman group including th

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that HDFC Mutual Fund: HDFC Prudence Fund, has acquired 25,000 shares aggregating to 0.18% of the total paid up capital of Dishman Pharmaceuticals and Chemicals Limited on June 09, 2005. The mode of acquisition is Market Purchase and the details of shareholding of HDFC Mutual Fund after the said acquisition is as follows: (i) HDFC Mutual Fund, Scheme - HDFC Prudence Fund holds 245,000 equity shares aggregating to 1.78% of the paid up share capital of Dishman Pharmaceuticals and Chemicals Limited; (ii) HDFC Mutual Fund: HDF

HDFC Asset Management Company Limited has informed the Exchange that HDFC Mutual Fund under its Scheme HDFC Prudence Fund, has acquired 25,000 shares aggregating to 0.18% of the total paid up capital of Dishman Pharmaceuticals and Chemicals Limited on June 09, 2005. The mode of acquisition is Market Purchase and the details of shareholding after the said acquisition is as follows: (i) HDFC Mutual Fund, Scheme - HDFC Prudence Fund holds 245,000 equity shares aggregating to 1.78% of the paid up share capital of Dishman Pharmaceuticals and Chemicals Limited; (ii) HDFC Mutual Fund, Scheme - HDFC E

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange of the details of the acquisition/sale as follows: 1) Sanjay S Majmudar, Director of the Company has acquired 4280 shares on May 30, 2005 through Off Market Purchase and his shareholding after the said acquisition is 4330 shares aggregating to 0.032% of the share capital of Dishman Pharmaceuticals and Chemicals Limited; 2) Ratna S Majmudar, Wife of Mr. Sanjay S Majmudar has acquired 2470 shares on May 31, 2005 through Off Market Purchase and her shareholding after the said acquisition is 2470 shares aggregating to 0.0180%

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the EGM held on June 03, 2005, the shareholders (Members) of the Company have passed three resolutions, without any modification, as stated in the Notice of the EGM (Notice dated May 08, 2005). These resolutions were pertaining to: 1. Approval for the issue of Foreign Currency Convertible Bonds (FCCBs) [Members of the Company have approved the same by passing a Special Resolution]; 2.Approval under section 293(1)[d] of the Companies Act, 1956, for enhancing the Borrowing Limit up to Rs. 750 Crores (consent of the M